The Role of FDG-PET/CT in Ovarian Cancer Patients with High Tumor Markers or Suspicious Lesion on Contrast-Enhanced CT in Evaluation of Recurrence and/or in Determination of Intraabdominal Metastases

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 31, Issue 1, 2012, Pages 3-8

  Sari, O ^a   Kaya, B ^a   Ozcan Kara, P ^a   Kara Gedik, G ^a   Celik, C ^a   Ozbek, O ^a   Serdengecti, M ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

CA 125; CeCT; Ovarian carcinoma; PET CT

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; BIOPSY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; EVALUATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; METASTASIS; OVARY CANCER; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84864295757     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2011.03.008     Document Type: Article

References (28)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Chang W.C., Hung Y.C., Kao C.H., Yen R.F., Shen Y.Y., Lin C.C. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002, 49:329-333.
3. Torizuka T., Nobezawa S., Kanno T., Futatsubashi M., Yoshikawa E., Okada H. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 2002, 29:797-803.
4. Shaaban A., Rezvani M. Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol 2009, 52:73-93.
5. Lynch T.B. PET/CT in Clinical Practice 2007, Springer, London, p. 157-214.
6. Dachman A.H., Visweswaran A., Battula R., Jameel S., Waggoner S.E. Role of chest CT in the follow-up of ovarian adenocarcinoma. AJR Am J Roentgenol 2001, 176:701-705.
7. Sella T., Rosenbaum E., Edelmann D.Z., Agid R., Bloom Al, Libson E. Value of chest CT scans in routine ovarian carcinoma follow-up. AJR Am J Roentgenol 2001, 177:857-859.
8. Zanon C., Clara R., Chiappino I., Bortolini M., Cornaglia S., Simone P., et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004, 28:1040-1045.
9. Park C.M., Kim S.H., Kim S.H., Moon M.H., Kim K.W., Choi H.J. Recurrent ovarian malignancy: patterns and spectrum of imaging findings. Abdom Imaging 2003, 28:404-415.
10. Bast R.C., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B. CA 125 the past and the future. Int J Biol Markers 1998, 13:179-187.
11. Santillan A., Garg R., Zahurak M.L., Gardner G.J., Guintoli R.L., Armstrong D.K., et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005, 23:9338-9343.
12. Meyer T., Rustin J.G. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000, 182:1535-1538.
13. Banerjee S., Gore M. Gynecological Cancer. Textbook of Medical Oncology 2009, 106-114. İnforma, London. 4th ed. F. Cavalli, S.B. Kaye, H.H. Hansen, J.O. Armitage, M.J. Piccart-Gebbert (Eds.).
14. Smith G.T., Hubner K.F., McDonald T., Thie J.A. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 1999, 2:63-70.
15. Yoshida Y., Kurokawa T., Kawahara K., Tsuchida T., Okazawa H., Fujibayashi Y., et al. Incremental benefits of FDG positron emission tomography ovarian CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004, 182:227-233.
16. Hubner K.F., McDonald T.W., Niethammer J.G., Smith G.T., Gould H.R., Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993, 51:197-204.
17. Schröder W., Zimny M., Rudlowski C., Büll U., Rath W. The role of 18-F-fluorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma. Int J Gynecol Cancer 1999, 9:117-122.
18. Kim S., Chung J.K., Kang S.B., Kim M.H., Jeong J.M., Lee D.S., et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004, 31:196-201.
19. Sironi S., Messa C., Mangili G., Zangheri B., Aletti G., Garavaglia E., et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004, 233:433-440.
20. Murakami M., Miyamoto T., Lida T., Tsukada H., Watanabe M., Shida M., et al. Wholebody positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006, 16:99-107.
21. Pannu H.K., Bristow R.E., Cohade C., Fishman E.K., Wahl R.L. PET-CT in Recurrent Ovarian Cancer: Initial Observations. Radiographics 2004, 24:209-223.
22. Simcock B., Neesham D., Quinn M., Drummond E., Milner A., Hicks R.J. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006, 103:271-276.
23. Takekuma M., Maeda M., Ozawa T., Yasumi K., Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005, 10:177-181.
24. Pan H.S., Lee S.L., Huang L.W., Chen Y.K. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet 2011, 283:335-341.
25. Bilici A., Ustaalioglu B.B.O., Seker M., Canpolat N., Tekinsoy B., Salepci T., et al. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?. Eur J Nucl Med Mol Imaging 2010, 37:1259-1269.
26. Nanni C., Rubello D., Farsad M., De laco P., Sansovini M., Erba P., et al. 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. EJSO 2005, 31:792-797.
27. Chung H.H., Kong W.J., Kim J.W., Park N.H., Song Y.S., Chung J.K., et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007, 34:480-486.
28. Thrall M., DeLoia J.A., Gallion H., Avril N. Clinical use of combined positron emission tomography and computed tomography (PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007, 105:17-22.